StockNews.AI
AMD
StockNews.AI
133 days

Age-related Macular Degeneration Market Report 2025-2030 - Asia-Pacific and EMEA Fuel Growth in AMD Market with Reforms and Expanding Access to Vision Care

1. AMD market size is projected to grow from $11.1B in 2024 to $16.43B by 2030. 2. Innovations in AMD treatments emphasize precision medicine and patient-centered approaches. 3. Regional market growth reflects varied healthcare infrastructure and early diagnosis advancements. 4. Established companies are leading in AMD management with investments in research. 5. Strategic collaborations are crucial for breakthroughs and market share enhancement.

14m saved
Insight
Article

FAQ

Why Bullish?

With a positive market growth forecast and ongoing innovations, AMD's competitive positioning may strengthen. Historical data shows similar trends have benefited tech companies in the healthcare space, suggesting a potential rise in stock performance.

How important is it?

The article signifies a transformative period for AMD treatments, directly related to potential growth impacting AMD's market strategy. The increasing need for innovations and market positioning can substantially drive investor interest.

Why Long Term?

While immediate impacts may vary, growing investments and market transitions signal sustained AMD market growth. Similar industry trends often take years to fully manifest in company valuations.

Related Companies

NVDAINTCQCOMTSM
Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration Market by Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), Treatment Modality (Pharmaceuticals, Surgical Interventions), Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.The Age-related Macular Degeneration Market grew from USD 10.45 billion in 2023 to USD 11.10 billion in 2024. It is expected to continue growing at a CAGR of 6.67%, reaching USD 16.43 billion by 2030.Recent years have witnessed dramatic changes in the landscape of age-related macular degeneration management. A combination of scientific breakthroughs and technological advancements is driving a paradigm shift that redefines therapeutic approaches and market potential. Ongoing developments in diagnostic imaging and molecular biology have paved the way for early detection strategies and more nuanced patient profiling. This evolution has led to earlier intervention protocols, significantly altering the treatment trajectory for patients affected by both dry and wet forms of AMD.Parallel to clinical innovations, there has been a substantial transition in patient care models and healthcare infrastructure. The traditional reactive approach to retinal diseases has given way to proactive, data-driven methodologies. A burgeoning emphasis on precision medicine ensures that treatments are increasingly tailored to individual patients based on genetic, demographic, and lifestyle factors, which in turn reshapes the competitive dynamics across pharmaceutical and surgical intervention spheres. Furthermore, partnerships between academic institutions, research organizations, and industry players are fostering cross-disciplinary collaborations that catalyze breakthrough discoveries.These market shifts also underscore the importance of adaptive strategies for stakeholders, as companies recalibrate their portfolios to incorporate emerging therapies and integrated treatment modalities. A comprehensive understanding of these transformative shifts provides continuous opportunities for investors and care providers to enhance patient outcomes while maximizing market share.Key Regional Trends and Emerging OpportunitiesThe analysis of regional trends highlights a diverse and evolving market landscape marked by unique regional characteristics and growth prospects. In North America, robust healthcare infrastructure coupled with a high prevalence of chronic conditions has streamlined early diagnosis and intervention for AMD. Continuous investments in research and development have ensured that the Americas remains at the forefront of innovative clinical trials and breakthrough therapies.Exploring the landscape across Europe, the Middle East, and Africa reveals a region where regulatory reforms and increased awareness have boosted market expansion. Intensive cross-border collaborations and public-private partnerships are catalyzing clinical advancements, while regional healthcare policies are adapting to support earlier diagnosis and more effective treatment modalities. Emerging economies within these regions are increasingly recognizing the importance of investing in modern ophthalmological care, thereby creating additional opportunities for market growth.The Asia-Pacific region presents another dynamic and rapidly expanding market segment. Economic growth, coupled with improved healthcare delivery systems and heightened consumer awareness, is driving a surge in demand for both conventional and advanced treatment options. Ongoing investments in healthcare infrastructure and localized research initiatives are further positioning the region as a key contributor to global market dynamics. As stakeholders leverage these regional insights, a comprehensive understanding of localized challenges and opportunities continues to inform strategic planning and resource allocation decisions.Leading Companies Shaping the Future of AMD ManagementThe dynamic landscape of age-related macular degeneration is reinforced by the active involvement of numerous established and emerging companies that are setting new benchmarks in vision care. The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include: AbbVie Inc.Adverum Biotechnologies, Inc.Alkeus Pharmaceuticals, Inc.Allegro Ophthalmics, LLCAmgen Inc.Annexon, Inc.Apellis Pharmaceuticals, Inc.AsclepiX TherapeuticsAstellas Pharma Inc.Bausch Health Companies Inc.Bayer AGBiocon LtdBiogen Inc.Clearside Biomedical, Inc.EyePoint Pharmaceuticals, Inc.F. Hoffmann-La Roche Ltd.Formycon AGGrifols, SAIonis Pharmaceuticals, Inc.Johnson & Johnson Services, Inc.Kodiak Sciences Inc.Lineage Cell Therapeutics, Inc.Lupin LimitedMerck & Co. Inc.Nicox SANovartis AGPanOptica, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Sandoz Group AGSun Pharmaceutical Industries, Ltd.Teva Pharmaceutical Industries Ltd.Viatris Inc. Strategic Recommendations for Industry LeadersIndustry leaders need to insulate themselves against market volatility while simultaneously embracing innovation to drive forward progress in the AMD space. Strategic recommendations suggest prioritizing robust clinical research to validate the emerging therapies and provide clear evidence of their efficacy through rigorous clinical trials. Investing in cutting-edge diagnostic modalities and fostering closer collaborations with academic institutions can provide valuable insights into the evolving biological pathways that underpin AMD.Leaders should also align their operational strategies with evolving regulatory frameworks that govern patient care and treatment innovations. Emphasizing agile supply chain management and ensuring the integrity of distribution channels can help companies balance risk while capitalizing on emerging market opportunities. Embracing digital technologies to streamline patient engagement and monitoring processes is equally crucial in today's technology-driven ecosystem.Diversifying portfolios across both pharmaceutical and surgical interventions, based on evolving treatment protocols, can mitigate risks associated with market saturation and competitive overlap. Industry stakeholders are advised to assess the merits of multi-channel distribution strategies that take into account variations in regional regulatory landscapes and consumer preferences. Integrating real-world evidence analytics into decision-making processes can further enhance market responsiveness and optimize resource allocation.In today's competitive environment, it is imperative that industry decision-makers adopt a holistic, data-driven approach. This means leveraging structured market segmentation insights and integrating them with robust forecasting models, while encouraging collaborative engagements across both public and private sectors. Such strategic imperatives are designed to fortify competitive positioning and ensure sustained growth in the long term.Key Attributes Report AttributeDetailsNo. of Pages185Forecast Period2024-2030Estimated Market Value (USD) in 2024$11.1 BillionForecasted Market Value (USD) by 2030$16.43 BillionCompound Annual Growth Rate6.6%Regions CoveredGlobal Key Topics Covered1. Preface2. Research Methodology3. Executive Summary4. Market Overview5. Market Insights5.1. Market Dynamics5.1.1. Drivers5.1.1.1. Growing number of geriatric population across the world5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD5.1.2. Restraints5.1.2.1. Potential risk of drug recalls associated with AMD5.1.3. Opportunities5.1.3.1. Significant government policies & funding for AMD5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering5.1.4. Challenges5.1.4.1. Stringent regulatory environment and complex approval of new treatments5.2. Market Segmentation Analysis5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care5.3. Porter's Five Forces Analysis5.3.1. Threat of New Entrants5.3.2. Threat of Substitutes5.3.3. Bargaining Power of Customers5.3.4. Bargaining Power of Suppliers5.3.5. Industry Rivalry5.4. PESTLE Analysis5.4.1. Political5.4.2. Economic5.4.3. Social5.4.4. Technological5.4.5. Legal5.4.6. Environmental5.5. Client Customization5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country6. Age-related Macular Degeneration Market, by Type6.1. Introduction6.2. Dry Age-Related Macular Degeneration6.3. Wet Age-Related Macular Degeneration7. Age-related Macular Degeneration Market, by Treatment Modality7.1. Introduction7.2. Pharmaceuticals7.2.1. Anti-inflammatory Drugs7.2.2. Anti-VEGF Agents7.2.3. Antioxidants & Supplements7.2.4. Gene Therapy Drugs7.3. Surgical Interventions7.3.1. Laser Therapy7.3.2. Macular Translocation Surgery7.3.3. Photodynamic Therapy7.3.4. Vitrectomy8. Age-related Macular Degeneration Market, by Delivery Method8.1. Introduction8.2. Injectable8.3. Intravitreal implants8.4. Oral9. Age-related Macular Degeneration Market, by Healthcare Setting9.1. Introduction9.2. Ambulatory Surgical Centers9.3. Hospitals9.4. Ophthalmology Clinics10. Age-related Macular Degeneration Market, by Distribution Channel10.1. Introduction10.2. Hospital Pharmacies10.3. Online Pharmacies10.4. Retail Pharmacies11. Americas Age-related Macular Degeneration Market11.1. Introduction11.2. Argentina11.3. Brazil11.4. Canada11.5. Mexico11.6. United States12. Asia-Pacific Age-related Macular Degeneration Market12.1. Introduction12.2. Australia12.3. China12.4. India12.5. Indonesia12.6. Japan12.7. Malaysia12.8. Philippines12.9. Singapore12.10. South Korea12.11. Taiwan12.12. Thailand12.13. Vietnam13. Europe, Middle East & Africa Age-related Macular Degeneration Market13.1. Introduction13.2. Denmark13.3. Egypt13.4. Finland13.5. France13.6. Germany13.7. Israel13.8. Italy13.9. Netherlands13.10. Nigeria13.11. Norway13.12. Poland13.13. Qatar13.14. Russia13.15. Saudi Arabia13.16. South Africa13.17. Spain13.18. Sweden13.19. Switzerland13.20. Turkey13.21. United Arab Emirates13.22. United Kingdom14. Competitive Landscape14.1. Market Share Analysis14.2. FPNV Positioning Matrix14.3. Competitive Scenario Analysis14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life14.4. Strategy Analysis & Recommendations14.4.1. F. Hoffmann-La Roche Ltd.14.4.2. Novartis AG14.4.3. Bayer AG14.4.4. Astellas Pharma Inc. For more information about this report visit https://www.researchandmarkets.com/r/me5euw About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News